Westfall Technik Acquires Multi-Site Consumer Packaging Molder CPP Global; Expands into North Carolina and China
2.7.2021 21:22:00 EEST | Business Wire | Press release
Westfall Technik, Inc. (“Westfall”, the “Company”), a global holding company that provides superior manufacturing solutions for the production of plastic parts in the medical, packaging, and consumer goods industries, announced today the acquisition of Carolina Precision Plastics, LLC (d/b/a “CPP Global” or “CPP”) and its wholly owned subsidiaries.
The deal greatly strengthens Westfall’s geographic footprint by adding its first plants in the southeastern United States, specifically in Mocksville and Asheboro, NC, as well in Kaiping, China, in Guangdong Province. “This provides a further supply-chain advantage to Westfall when it comes to serving key customers in both the packaging and healthcare sectors,” said Merritt Williams, the firm’s Chief Commercial Officer. “CPP’s North Carolina plants are ideally located to serve the multitude of brand owners with a manufacturing presence in the surrounding area.”
CPP, which runs about 100 injection molding machines in its three facilities, also brings expertise in vital secondary services, such as high-volume, fully automated assembly and sophisticated decorating capabilities. In total, CPP’s three plants cover some 335,000 square feet of manufacturing space.
“This is just the next step in creating a truly world-class molding and tooling business that is built on a strong culture and unquestionable customer service,” according to Westfall CEO and founder Brian Jones.
A leader in North America in the injection molding of heavy-wall PET jars, CPP also operates an innovative, collaborative design center and has a strong sustainability profile. The firm is a significant user of recycled resins and biopolymers in its products.
“This highly strategic, synergistic deal greatly strengthens our presence in the fast-moving consumer goods segment,” said Mark Gomulka, Westfall’s Chief Operating Officer. “CPP Global is a valued packaging supplier to several leading personal care and beauty companies, such as L’Oréal (serving their L’Oréal Paris and Kiehl’s brands), Estée Lauder, and Burt’s Bees, among others.”
For CPP Chief Executive Officer Brian Tauber, the partnership with Westfall offers a clear path forward for continuing the upward growth trend that CPP Global is experiencing right now. “I’m thrilled to combine our strengths with the breadth and depth of Westfall’s capabilities to enhance our ability to provide our employees, customers, and other stakeholders with more opportunities to grow together,” said Tauber.
The terms of the investment were not disclosed. Westfall was represented by Morrison Cohen LLP as legal counsel. CPP Global was represented by Sheppard, Mullin, Richter & Hampton LLP as legal counsel and Stifel as financial advisor.
About Carolina Precision Plastics, LLC
Carolina Precision Plastics is a global plastic injection molder in the beauty care, cosmetics, beverage and consumer goods markets, providing its customers molding, assembly and decorating capabilities built on a foundation of an industry-leading lean culture. Its global manufacturing presence and commitment to a more sustainable packaging future afford customers the most efficient and environmentally responsible options for their packaging needs. Central to its Lean North Stars, CPP’s journey focuses on providing value to its customers and ensuring a safe, satisfying work environment to its entire team. For more, visit www.cppglobal.com.
About Westfall Technik, Inc.
Westfall Technik is a global holding company that provides highly productive plastics manufacturing solutions to the medical, consumer packaging and consumer goods industries. Since its founding in Las Vegas in October 2017, the company has acquired or launched at least 19 businesses across North America. Westfall Technik’s competitive advantages include modern automated systems, correlative molding processes, and effective industry 4.0 concepts. Brand owners can expect high quality products at an excellent value, a fast response for decreased time-to-market, 100% inspection and traceability from pellet to pallet, supply-chain security compliance, and reliability from a trustworthy team. For more, visit www.westfall-technik.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210702005408/en/
Contact information
Merritt Williams, Chief Commercial Officer:
Merritt.Williams@Westfall-Technik.com or (502) 386-1399
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom